Medications and Surgical Interventions for Benign Prostatic Hyperplasia Are Potential Confounders of Prostate-Specific Antigen
- 15 May 2010
- journal article
- Published by Springer Science and Business Media LLC in Current Urology Reports
- Vol. 11 (4), 224-227
- https://doi.org/10.1007/s11934-010-0113-9
Abstract
Prostate-specific antigen (PSA) is the most widely used marker for prostate cancer (CaP) screening and monitoring benign prostatic hyperplasia (BPH) progression. However, lack of an established abnormal threshold and the presence of other benign processes confound the interpretation of PSA levels. Many factors besides inflammation, trauma, and instrumentation can influence PSA levels; specifically, BPH and its associated medical and surgical therapies frequently complicate the interpretation of this serum blood test. For example, the commonly used 5 alpha reductase inhibitor (5ARI) medications directly affect PSA levels by decreasing prostate volume. The amount of time and potentially even the 5ARI formulary a patient is administered has been implicated to directly impact the degree of reduction in PSA (a proxy for prostate volume). In addition, each of the currently available surgical procedures for BPH appears to remove varying amounts of prostatic adenoma. This directly confounds CaP screening because each procedure is associated with a relatively specific postoperative nadir PSA level, and PSA kinetics are not well described in the literature. Taken together, it is important for clinicians to comprehend that BPH and its associated medical and surgical interventions should directly influence their interpretation of PSA and PSA velocity when screening for CaP or following BPH progression.Keywords
This publication has 25 references indexed in Scilit:
- The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasiaInternational Journal Of Impotence Research, 2008
- Prediction of Prostate Cancer for Patients Receiving Finasteride: Results From the Prostate Cancer Prevention TrialJournal of Clinical Oncology, 2007
- Management of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia With Open Prostatectomy: Results of a Contemporary SeriesJournal of Urology, 2006
- Detection of Life-Threatening Prostate Cancer With Prostate-Specific Antigen Velocity During a Window of CurabilityJNCI Journal of the National Cancer Institute, 2006
- The Interpretation of Serum Prostate Specific Antigen in Men Receiving 5α-Reductase Inhibitors: A Review and Clinical RecommendationsJournal of Urology, 2006
- Clinical Usefulness of Serum Prostate Specific Antigen for the Detection of Prostate Cancer is Preserved in Men Receiving the Dual 5α-Reductase Inhibitor DutasterideJournal of Urology, 2006
- Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 gBJU International, 2005
- LONG-TERM EFFECTS OF FINASTERIDE ON PROSTATE SPECIFIC ANTIGEN LEVELS: RESULTS FROM THE PROSTATE CANCER PREVENTION TRIALJournal of Urology, 2005
- Change in Serum Prostate Specific Antigen Concentration after Holmium Laser Enucleation of the Prostate: A Marker for Completeness of Adenoma Resection?Journal of Endourology, 2005
- Transurethral Holmium Laser Enucleation Versus Transvesical Open Enucleation for Prostate Adenoma Greater Than 100 gm.: A Randomized Prospective Trial of 120 PatientsJournal of Urology, 2002